Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today.
Joseph Stringer has given his Hold rating due to a combination of factors including Vertex Pharmaceuticals’ recent financial performance and future outlook. The company reported a total revenue of $2.77 billion for the first quarter of 2025, which was a decline from the previous quarter and fell short of both Joseph’s and the consensus estimates. Additionally, the non-GAAP earnings per share also missed expectations, coming in at $4.06 compared to the anticipated $4.72.
Despite these misses, the company has narrowed its revenue guidance for 2025 to a range of $11.85 to $12.0 billion, indicating a more focused outlook. The launch of Journavx for acute pain is underway, with over 20,000 prescriptions filled, and is expected to be a significant growth driver in the coming year. However, Joseph Stringer maintains a Hold rating, suggesting that the current valuation and the balance of risks and rewards do not warrant a more aggressive stance on the stock at this time.
In another report released today, Leerink Partners also downgraded the stock to a Hold with a $503.00 price target.